Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.
2.

Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database.

Lorch A, Bascoul-Mollevi C, Kramar A, Einhorn L, Necchi A, Massard C, De Giorgi U, Fléchon A, Margolin K, Lotz JP, Germà-Lluch JR, Powles T, Kollmannsberger C, Beyer J.

J Clin Oncol. 2011 Jun 1;29(16):2178-84. doi: 10.1200/JCO.2010.32.6678.

PMID:
21444870
4.

Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors.

Narayan V, Gunnarsson O, Hwang WT, Squillante CM, Nathanson KL, Stadtmauer EA, Vaughn DJ.

Clin Genitourin Cancer. 2016 Dec;14(6):524-529. doi: 10.1016/j.clgc.2016.03.015.

PMID:
27083130
5.

Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.

Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ, Bajorin DF, Lara PN Jr, Einhorn L, Mazumdar M, Bosl GJ.

J Clin Oncol. 2007 Jan 20;25(3):247-56.

PMID:
17235042
6.

High-dose chemotherapy with autologous stem cell transplantation in relapsed or refractory germ cell tumours: outcomes and prognostic variables in a case series of 17 patients.

Lewin J, Dickinson M, Voskoboynik M, Collins M, Ritchie D, Toner G.

Intern Med J. 2014 Aug;44(8):771-8. doi: 10.1111/imj.12486.

PMID:
24893627
7.

High-dose chemotherapy followed by hematological support: experience in the treatment of germ cell tumors.

Pico JL, Fadel E, Ibrahim A, Bourhis JH, Droz JP.

Bull Cancer. 1995;82 Suppl 1:56s-60s. Review.

PMID:
7542945
8.

Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.

Fosså SD, Stenning SP, Gerl A, Horwich A, Clark PI, Wilkinson PM, Jones WG, Williams MV, Oliver RT, Newlands ES, Mead GM, Cullen MH, Kaye SB, Rustin GJ, Cook PA.

Br J Cancer. 1999 Jul;80(9):1392-9.

9.
10.

Long-term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy.

Beyer J, Kingreen D, Krause M, Schleicher J, Schwaner I, Schwella N, Huhn D, Siegert W.

Cancer. 1997 Jan 1;79(1):161-8.

PMID:
8988741
11.

High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA).

Haugnes HS, Laurell A, Stierner U, Bremnes RM, Dahl O, Cavallin-Ståhl E, Cohn-Cedermark G.

Acta Oncol. 2012 Feb;51(2):168-76. doi: 10.3109/0284186X.2011.641507.

PMID:
22175254
12.
13.

Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.

Motzer RJ, Mazumdar M, Gulati SC, Bajorin DF, Lyn P, Vlamis V, Bosl GJ.

J Natl Cancer Inst. 1993 Nov 17;85(22):1828-35.

PMID:
7693955
14.

Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy.

International Prognostic Factors Study Group., Lorch A, Beyer J, Bascoul-Mollevi C, Kramar A, Einhorn LH, Necchi A, Massard C, De Giorgi U, Fléchon A, Margolin KA, Lotz JP, Germa Lluch JR, Powles T, Kollmannsberger CK.

J Clin Oncol. 2010 Nov 20;28(33):4906-11. doi: 10.1200/JCO.2009.26.8128.

PMID:
20956623
15.

Long-term outcome of salvage high-dose chemotherapy in patients with germ cell tumor with poor prognostic features.

De Giorgi U, Rosti G, Salvioni R, Papiani G, Ballardini M, Pizzocaro G, Marangolo M.

Urol Oncol. 2011 May-Jun;29(3):284-90. doi: 10.1016/j.urolonc.2009.03.030.

PMID:
19556152
16.

Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor?

Banna GL, De Giorgi U, Ferrari B, Castagna L, Alloisio M, Marangolo M, Rosti G, Santoro A.

Biol Blood Marrow Transplant. 2006 Oct;12(10):1085-91.

17.

Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group.

Lorch A, Kollmannsberger C, Hartmann JT, Metzner B, Schmidt-Wolf IG, Berdel WE, Weissinger F, Schleicher J, Egerer G, Haas A, Schirren R, Beyer J, Bokemeyer C, Rick O; German Testicular Cancer Study Group..

J Clin Oncol. 2007 Jul 1;25(19):2778-84.

PMID:
17602082
18.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Review.

PMID:
12042984
19.

Prognostic factors in patients with relapsed or primary refractory germ cell tumors.

Rejlekova K, Mego M, Sycova-Mila Z, Obertova J, Rajec J, Salek T, Mardiak J.

Neoplasma. 2009;56(3):215-23.

PMID:
19309224
20.

Future prospects in the chemotherapy of metastatic nonseminomatous testicular germ-cell cancer.

Hartmann JT, Kuczyk MA, Kollmannsberger C, Kanz L, Bokemeyer C.

World J Urol. 1999 Oct;17(5):324-33. Review.

PMID:
10552153
Items per page

Supplemental Content

Support Center